Therapeutic effects of lenvatinib in combination with rAd‑p53 for the treatment of non‑small cell lung cancer

Yu,Renzhi; Wang,Minghuan; Zhu,Xiuli; Sun,Zhe; Jiang,Aiying; Yao,Huixin

doi:10.3892/ol.2018.9428

Therapeutic effects of lenvatinib in combination with rAd‑p53 for the treatment of non‑small cell lung cancer

Authors:
- Renzhi Yu
- Minghuan Wang
- Xiuli Zhu
- Zhe Sun
- Aiying Jiang
- Huixin Yao
View Affiliations

Affiliations: Department of Respiratory Medicine, Mudanjiang Medical University Affiliated HongQi Hospital, Mudanjiang, Heilongjiang 157000, P.R. China, Community Health Service Center, Medical University Affiliated HongQi Hospital, Mudanjiang, Heilongjiang 157000, P.R. China, Department of Insurance, Mudanjiang Medical University Affiliated HongQi Hospital, Mudanjiang, Heilongjiang 157000, P.R. China, Department of Medicine, Mudanjiang Medical University Affiliated HongQi Hospital, Mudanjiang, Heilongjiang 157000, P.R. China
Published online on: September 11, 2018 https://doi.org/10.3892/ol.2018.9428
Pages: 6573-6581
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze the effects of the combined treatment of lenvatinib and adenoviral delivered p53 gene (rAd‑p53) on non‑small cell lung cancer (NSCLC) cells and a total of 120 patients with NSCLC. The therapeutic effects of gene therapy of rAd‑p53 and target therapy of Lenvatinib were investigated in NSCLC patients. The anti‑tumor effects of combined treatment of llenvatinib and rAd‑p53 was administered orally once‑daily in NSCLC patients. Patients with NSCLC were divided into three groups and received lenvatinib (n=40), rAd‑p53 (n=40) or combined treatment of lenvatinib and rAd‑p53 (n=40) for a total of 30 days. Results showed that p53 was down‑regulated and VEGFR, FGFR and PDGFR‑β were up‑regulated in NSCLC tissues compared to adjacent normal tissues. Combined treatment of Lenvatinib and rAd‑p53 markedly inhibited NSCLC cell growth, migration and invasion, and promoted apoptosis compared to either lenvatinib or rAd‑p53 alone. The most common treatment‑related adverse events included hypertension, diarrhea, nausea, proteinuria and body weight loss. Outcomes indicated that combined treatment of lenvatinib and rAd‑p53 markedly inhibited tumor growth compared to lenvatinib and rAd‑p53 alone for NSCLC patients. Combined treatment of lenvatinib and rAd‑p53 did not exhibit drug accumulation after 30‑day treatment. In conclusion, these outcomes indicate that combined treatment of lenvatinib and rAd‑p53 may be an efficient therapeutic schedule for the treatment of NSCLC patients.

View Figures

View References

1	Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X and Kato T: Real-world practice patterns for patients with advancednon-small cell lung cancer: Multicenter retrospective cohort study in Japan. Lung Cancer (Auckl). 8:191–206. 2017.PubMed/NCBI
2	Prince RM, Atenafu EG and Krzyzanowska MK: Hospitalizations during systemic therapy for metastatic lung cancer: A systematic review of real world vs clinical trial outcomes. JAMA Oncol. 1:1333–1339. 2015. View Article : Google Scholar : PubMed/NCBI
3	Brody H: Lung cancer. Nature. 513:S12014. View Article : Google Scholar : PubMed/NCBI
4	Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
5	Barnett SA, Downey RJ, Zheng J, Plourde G, Shen R, Chaft J, Akhurst T, Park BJ and Rusch VW: Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer. Ann Thorac Surg. 101:1052–1059. 2016. View Article : Google Scholar : PubMed/NCBI
6	Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, et al: Characteristics, treatment patterns and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. Lung Cancer. 98:9–14. 2016. View Article : Google Scholar : PubMed/NCBI
7	Saadeddin A: Radiotherapy for NSCLC: Review of conventional and new treatment techniques. J Infect Public Health. 5 Suppl 1:S45–S49. 2012. View Article : Google Scholar : PubMed/NCBI
8	van Meerbeeck JP and Surmont VF: Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments. Lung Cancer. 65:257–267. 2009. View Article : Google Scholar : PubMed/NCBI
9	Bianco A, Tridico F, Rebecchi F, Contessa L, Fusca M, Calello G, Monticone C, De Rocca C, Suffat Panier L, Giaccone C and Suffat Panier P: Adrenal synchronous metastasis from non small cell lung carcinoma (NSCLC): Combined surgical treatment? Case report and review of the literature. Minerva chir. 56:535–537. 2001.(In Italian). PubMed/NCBI
10	Li Y, Li LJ, Wang LJ, Zhang Z, Gao N, Liang CY, Huang YD and Han B: Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial. BMC Med. 12:162014. View Article : Google Scholar : PubMed/NCBI
11	Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D and Pegram M: A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9:553–566. 2002. View Article : Google Scholar : PubMed/NCBI
12	Liu K, Zhao J, Jiang H, Ma J, Tan J, Pei Y and Chen J: A patient with a large intrathoracic malignant schwannoma who showed a complete clinical response to rAd-p53-combined with radiotherapy. Anticancer Drugs. 26:902–906. 2015. View Article : Google Scholar : PubMed/NCBI
13	Chen GX, Zheng LH, Liu SY and He XH: rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. World J Gastroenterol. 17:4289–4297. 2011. View Article : Google Scholar : PubMed/NCBI
14	Du CH, Wu Z and Xu J: The combination of recombinant rAd-p53 and adriamycin for management of primary drug resistance in chemotherapy of lung squamous cell cancer. Zhonghua Jie He He Hu Xi Za Zhi. 29:622–624. 2006.(In Chinese). PubMed/NCBI
15	Guan YS, Liu Y, Zou Q, He Q, La Z, Yang L and Hu Y: Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J Zhejiang Univ Sci B. 10:331–340. 2009. View Article : Google Scholar : PubMed/NCBI
16	Takasu S, Mutoh M, Takahashi M and Nakagama H: Lipoprotein lipase as a candidate target for cancer prevention/therapy. Biochem Res Int. 2012:3986972012. View Article : Google Scholar : PubMed/NCBI
17	Miyazono K: Ectodomain shedding of HB-EGF: A potential target for cancer therapy. J Biochem. 151:1–3. 2012. View Article : Google Scholar : PubMed/NCBI
18	Sebens S and Schafer H: The tumor stroma as mediator of drug resistance-a potential target to improve cancer therapy? Curr Pharm Biotechnol. 13:2259–2272. 2012. View Article : Google Scholar : PubMed/NCBI
19	O'Reilly A and Larkin J: Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert Rev Clin Pharmacol. 10:251–262. 2017.PubMed/NCBI
20	Kuznar W: Lenvatinib extends survival in metastatic renal-cell carcinoma. Am Health Drug Benefits. 8:182015.PubMed/NCBI
21	Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, et al: Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer. 109:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
22	Nagashima S, Matsuo S, Takahashi M, Umemoto Y, Hirano T, Enomoto K, Sakurai K and Amano S: Effectiveness of lenvatinib for thyroid cancer with lung Metastases -report of a case. Gan To Kagaku Ryoho. 43:2121–2123. 2016.(In Japanese). PubMed/NCBI
23	Halim NHA, Zakaria N, Satar NA and Yahaya BH: Isolation and characterization of cancer stem cells of the non-small-cell lung cancer (A549) cell line. Methods Mol Biol. 1516:371–388. 2016. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Deng B, Sun T, Tang B, Tao S, Kang P, Qian K, Jiang B, Li K, Li K, Zhou J, et al: Surgery combined with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: A phase II study. Oncotarget. 8:107089–107095. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ghantous Y, Naddaf R, Barak M, Abd-Elraziq M and AbuEln-Naaj I: The role of fine needle aspiration in the diagnosis of parotid gland tumors: Correlation with preoperative computerized tomography tumor size. J Craniofac Surg. 27:e192–e196. 2016. View Article : Google Scholar : PubMed/NCBI
27	Solbach C, Roller M, Peters S, Nicoletti M, Kaufmann M and Knecht R: Pituitary tumor-transforming gene (PTTG): A novel target for anti-tumor therapy. Anticancer Res. 25:121–125. 2005.PubMed/NCBI
28	Mayor S: Lenvatinib improves survival in refractory thyroid cancer. Lancet Oncol. 16:e1102015. View Article : Google Scholar : PubMed/NCBI
29	Xie Q, Liang BL, Wu YH, Zhang J, Chen MW, Liu HY, Gu XF and Xu J: Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene. 499:303–308. 2012. View Article : Google Scholar : PubMed/NCBI
30	Luo SH, Zheng CS, Feng GS, Sun XM, Zhou GF, Liang HM, Xia XW and Fang JL: Experimental studies of rAd-p53 injection by interventional approach for the treatment of rabbit VX2 liver cancer. Zhonghua Gan Zang Bing Za Zhi. 18:502–505. 2010.(In Chinese). PubMed/NCBI
31	Lee H, Kim Y, Jeong JH, Ryu JH and Kim WY: ATM/CHK/p53 pathway dependent chemopreventive and therapeutic activity on lung cancer by pterostilbene. PLoS One. 11:e01623352016. View Article : Google Scholar : PubMed/NCBI
32	Li W, Yang Y, Ouyang Z, Zhang Q, Wang L, Tao F, Shu Y, Gu Y, Xu Q and Sun Y: Xiao-Ai-Ping, a TCM injection, enhances the antigrowth effects of cisplatin on lewis lung cancer cells through promoting the infiltration and function of CD8(+) T lymphocytes. Evid Based Complement Alternat Med. 2013:8795122013. View Article : Google Scholar : PubMed/NCBI
33	Jia J, Dellinger AE, Weiss ES, Bulusu A, Rushing C, Li H, Howard LA, Kaplan N, Pang H, Hurwitz HI and Nixon AB: Direct Evidence of Target Inhibition with Anti-VEGF, EGFR and mTOR Therapies in a Clinical Model of Wound Healing. Clin Cancer Res. 21:3442–3452. 2015. View Article : Google Scholar : PubMed/NCBI
34	Shibuya M: Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2:1097–1105. 2011. View Article : Google Scholar : PubMed/NCBI
35	Canavese M, Altruda F, Ruzicka T and Schauber J: Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-a possible target for novel therapies? J Dermatol Sci. 58:171–176. 2010. View Article : Google Scholar : PubMed/NCBI
36	Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014:6387472014. View Article : Google Scholar : PubMed/NCBI